Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION

v3.22.2.2
SEGMENT INFORMATION
 9 Months Ended
Jul. 31, 2022
Segment Reporting [Abstract]  
SEGMENT INFORMATION

10. SEGMENT INFORMATION

 

We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in four reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics and (iv) Other. The following represents selected financial information for our segments for the three and nine months ended July 31, 2022 and 2021 and as of July 31, 2022 and October 31, 2021, in thousands:

                                 
   

For the Three Months

Ended July 31,

     For the nine Months
Ended July 31,		  
    2022     2021     2022     2021  
Net Loss:                                
CAR-T Therapeutics   $ (965 )   $ (1,619 )   $ (3,975 )   $ (4,025 )
Cancer Vaccines     (903 )     (1,464 )     (3,684 )     (3,033 )
Anti-Viral Therapeutics     (904 )     (1,262 )     (2,565 )     (2,053 )
Other     (3 )     (43 )     (18 )     54  
Total   $  (2,775 )   $ (4,388 )   $ (10,242 )   $ (9,057 )
                                 
Total operating costs and expenses   $ 2,797     $ 4,388     $ 10,266     $ 9,572  
Less non-cash share-based compensation     (1,438 )     (3,187 )     (5,474 )     (5,225 )
Operating costs and expenses excluding non-cash share-based compensation   $ 1,359     $ 1,201     $ 4,792     $ 4,347  
Operating costs and expenses excluding non-cash share based compensation:                                
CAR-T Therapeutics   $ 425     $ 411     $ 1,852     $ 1,904  
Cancer Vaccines     378       349       1,598       1,185  
Anti-Viral Therapeutics     554       418       1,328       827  
Other     2       23       14       431  
Total   $ 1,359     $ 1,201     $ 4,792     $ 4,347  

 

                 
    July 31,
2022		     October 31,
2021		  
Total assets:                
CAR-T Therapeutics   $ 13,656     $ 15,068  
Cancer Vaccines     7,606       13,276  
Anti-Viral Therapeutics     11,169       7,368  
Other     132       545  
Total   $ 32,563     $ 36,257  

 

Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.

 

The Company’s consolidated revenue of $513,000 and inventor royalties, contingent legal fees, litigation and licensing expense of $385,000 for the nine months ended July 31, 2021 were solely related to our encrypted audio/video conference calling technology, which is included in our Other segment. All our revenue is generated domestically (United States) based on the country in which the licensee is located.